Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical
aesthetic and therapeutic skin health systems, today announced that its
second quarter 2009 financial results will be released after the market
close on Thursday, August 6, and will be followed by an investor
conference call on the same day at 4:30 p.m. Eastern time (1:30 p.m.
Pacific time).
Investors interested in participating in the live call can dial
877-941-6010 from the U.S. International callers can dial 480-629-9772.
A telephone replay will be available approximately two hours after the
call concludes through Thursday, August 20, by dialing 800-406-7325 from
the U.S., or 303-590-3030 for international callers, and entering
confirmation code 4117088.
There also will be a simultaneous webcast available on the Investor
Relations section of the Company's web site at www.obagi.com.
For those unable to participate during the live broadcast, the webcast
will be archived for 30 days.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products
for the dermatology, plastic surgery, and related aesthetic markets.
Using its Penetrating Therapeutics™ technologies, Obagi Medical's
products are designed to improve penetration of agents across the skin
barrier for common and visible skin conditions in adult skin including
chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The
history of Obagi's skin care product introductions is as follows: Obagi
Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength
vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line
of highly stable vitamin C serums), 2005; Obagi® Condition and Enhance
for use with cosmetic procedures to enhance patient outcomes and
satisfaction, 2006; Obagi ELASTIderm™ eye treatment and Obagi
CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi
CLENZIderm® M.D. Systems for normal to dry skin, June 2007; Obagi
ELASTIderm™ Décolletage System, January 2008; and the Obagi® Rosaclear™
System for Rosacea in January 2009. Visit www.obagi.com
for more information.
Obagi Medical Products, Inc.
Preston Romm
CFO, EVP of Finance,
Operations and Administration
562-628-1007
or
Investors:
ICR,
Inc.
Ina McGuinness/Lena Adams
310-954-1100
